根治性膀胱切除术治疗的尿路上皮膀胱癌中变异组织学的预后影响
多中心队列分析1082例接受根治性膀胱切除术的cT1-4aN0M0尿路上皮膀胱癌患者,27.5%存在变异组织学。总体上,浆细胞样和小细胞变异与更差疾病特异性生存相关(均P=0.04),透明细胞在器官局限期、小细胞在淋巴结阳性期分别与更差DSS相关;淋巴上皮瘤样变异则显示生存获益。
要点
- 1082例根治性膀胱切除患者中298例(27.5%)存在变异组织学,鳞状分化最常见(166例,15.3%)。
- 总体队列中浆细胞样和小细胞变异与更差疾病特异性生存独立相关(均P=0.04)。
- 透明细胞变异在器官局限期(P=0.015)、小细胞变异在淋巴结阳性期(P=0.011)与更差DSS相关。
核心结论
- 超过25%的患者在根治性膀胱切除术时存在变异组织学。
- 与纯尿路上皮癌相比,透明细胞、浆细胞样、小细胞和肉瘤样变异与更差疾病特异性生存相关,而淋巴上皮瘤样变异则显示生存获益。
- 准确的变异组织学病理诊断可能有助于定制咨询,以识别需要更强化管理的患者。
研究设计与样本
- 多中心队列研究,纳入8个中心1082例因cT1-4aN0M0尿路上皮膀胱癌接受 upfront 根治性膀胱切除术的患者。
- 采用单变量和多变量Cox回归分析评估不同变异组织学对总体队列及三个分期亚组疾病特异性生存的影响。
- 分期定义为器官局限(≤pT2N0)、局部进展(pT3-4N0)和淋巴结阳性(pTanyN1-3)。
主要发现
- 总体784例(72.5%)为纯尿路上皮癌,298例(27.5%)存在变异组织学。
- 鳞状分化为最常见变异,166例(15.3%),其次为微乳头40例(3.7%)、肉瘤样29例(2.7%)、腺样18例(1.7%)、淋巴上皮瘤样14例(1.3%)、小细胞13例(1.2%)、透明细胞8例(0.7%)、巢状7例(0.6%)和浆细胞样3例(0.3%)。
- 中位随访2.3年,共发生534例(49.4%)疾病相关死亡。
- 单变量和多变量分析中,浆细胞样和小细胞变异与总体队列更差DSS相关(均P=0.04)。
- 单变量分析中,肉瘤样变异与更差DSS显著相关,而淋巴上皮瘤样变异相比纯尿路上皮癌具有更有利的DSS。
关键数值与推荐
- 总体队列中浆细胞样和小细胞变异与更差DSS相关(均P=0.04)。
- 器官局限期透明细胞变异与更差DSS相关(P=0.015)。
- 淋巴结阳性期小细胞变异与更差DSS相关(P=0.011)。
临床怎么用
- 准确的变异组织学病理诊断可能有助于定制咨询,以识别需要更强化管理的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC). MATERIALS AND METHODS: We analysed a multi-institutional cohort of 1082 patients treated with upfront RC for cT1-4aN0M0 urothelial BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect of different VHs on DSS in overall cohort and three stage-based analyses. The stages were defined as 'organ-confined' (≤pT2N0), 'locally advanced' (pT3-4N0) and 'node-positive' (pTanyN1-3). RESULTS: Overall, 784 patients (72.5%) had pure urothelial carcinoma (UC), while the remaining 298 (27.5%) harboured a VH. Squamous differentiation was the most common VH, observed in 166 patients (15.3%), followed by micropapillary (40 patients [3.7%]), sarcomatoid (29 patients [2.7%]), glandular (18 patients [1.7%]), lymphoepithelioma-like (14 patients [1.3%]), small-cell (13 patients [1.2%]), clear-cell (eight patients [0.7%]), nested (seven patients [0.6%]) and plasmacytoid VH (three patients [0.3%]). The median follow-up was 2.3 years. Overall, 534 (49.4%) disease-related deaths occurred. In uni- and multivariable analyses, plasmacytoid and small-cell VHs were associated with worse DSS in the overall cohort (both P = 0.04). In univariable analyses, sarcomatoid VH was significantly associated with worse DSS, while lymphoepithelioma-like VH had favourable DSS compared to pure UC. Clear-cell (P = 0.015) and small-cell (P = 0.011) VH were associated with worse DSS in the organ-confined and node-positive cohorts, respectively. CONCLUSIONS: More than 25% of patients harboured a VH at time of RC. Compared to pure UC, clear-cell, plasmacytoid, small-cell and sarcomatoid VHs were associated with worse DSS, while lymphoepithelioma-like VH was characterized by a DSS benefit. Accurate pathological diagnosis of VHs may ensure tailored counselling to identify patients who require more intensive management.
引用
- Claps F, van de Kamp MW, Mayr R, et al. Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy. BJU Int. 2023. PMID: 36748180. doi:10.1111/bju.15984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。